



MAY 1 4 2003

Approved for use through 04/30/2003. OMB 0651-0031 1600/2900

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE der the Papersonk Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO Complete if Known **Application Number** 09/944,163 INFORMATION DISCLOSURE Filing Date August 30, 2001 STATEMENT BY APPLICANT **First Named Inventor** Schall, Thomas J., et. al. Art Unit (use as many sheets as necessary) **Examiner Name** Jiang, S. Anna 2 019934-000310US Page Attorney Docket Number

U.S. PATENT DOCUMENTS								
		Document Number	-					
Examiner	Cite No.1	Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Wher Relevant Passages or Relevan Figures Appear			
529	AA	US-6,420,121 B1	07/16/2002	J. Nelson et al.				
	AB	US-3,379,729	04/23/1968	M. Protiva et al.				
	AC	US-09/944,051		T. Schall et al.				
	AD	US-10/233,326		B. McMaster et al.				
	ΑE	US-10/233,336		B. McMaster et al.				
20	AF	US-10/061,943		T. Schall et al.				

			FOREIGN PA	TENT DOCUM	ENTS		
	0.11	Foreign Patent Document			Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	I -
	Cite No. ¹	Country Code ³	Number ⁴ Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY Applicant of Cited Document			T⁵
398	AG	PCT	WO 00/11950	03/09/2000	Oregon Health Science University		
	AH	PCT	WO 02/17900 A2	03/07/2002	ChemoCentryx, Inc.		
	Al	PCT	WO 02/17969 A2	03/07/2002	ChemoCentryx, Inc.		
	AJ	PCT	WO 02/18954 A2	03/07/2002	ChemoCentryx, Inc.		
	AK	PCT	WO 98/02151	01/22/1998	Leukosite, Inc.		
508	AL	PCT	WO 00/00491	01/06/2000	The Regents of the University of California		

Examiner Signature	509	Date Considered	7/23/62	
·				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. Enter

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



ersons are required to respond to a collection of information unless it contains a valid OMB control number

MAY 1 4 2003

Approved for use through 04/30/2003. OMB 065 F003 0
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwolk Reduction Act of 1995, pl

Substitute for form 1449/PTO Complet if Known **Application Number** 09/944,163 INFORMATION DISCLOSURE Filing Date August 30, 2001 STATEMENT BY APPLICANT **First Named Inventor** Schall, Thomas J., et. al. 1617 Art Unit (use as many sheets as necessary) **Examiner Name** Jiang, S. Anna of Attorney Docket Number 019934-000310US Page

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SAY	АМ	Beisser, P.S., et al., "Viral Chemokine Receptors and Chemokines in Human Cytomegalovirus Trafficking and Interaction with the Immune System," Curr. Top. Microbiol. Immunol., Vol. 269, (2002), pp. 203-234.	
	AN	Chee, M.S., et al., "Analysis of the Protein-Coding Content of the Sequence of Human Cytomegalovirus Strain AD169," Curr. Top. Microbiol. Immunol., Vol. 154, (1990), pp. 125-169	
	AO	Francken, Bart J. B., et al., "Human 5-Hydroxytryptamine _{5A} Receptors Activate Coexpressed G _i and G _o Proteins in Spodoptera frugiperda 9 Cells", Molecular Pharmacology, Vol. 57, No. 5, pp. 1034-1044 (May 2000).	
	AP	Horuk, Richard, "Molecular properties of the chemokine receptor family", <i>Trends Pharm. Sci.</i> , Vol. 15, (1994), pp. 159-165.	
	AQ	Kledal, T. N., et al., "Selective recognition of the membrane-bound CX ₃ C chemokine, fractalkine, by the human cytomegalovirus-encoded broad-spectrum receptor US28," FEBS Letters, Vol. 441, (1998), pp. 209-214.	
	AR	Kung, H. F., et al., "Dopamine D-2 Receptor Imaging Radiopharmaceuticals: Synthesis, Radiolabeling, and in Vigro Biding of (R)-(+)- and (S)-(-)-3-lodo-2-hydroxy-6-methoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl]benzamido, J. of Medicinal Chemistry, Vol. 31, No. 5, (1988), pp. 1039-1042.	
	AS	McNall, Steven J. and Mansour, Tag E., "Novel Serotonin Receptors in Fasciola: Characterization by Studies on Adenylate Cyclase Activation and [3H]LSD Binding", Biochemical Pharmacology, Vol. 33, No. 17, pp. 2789-2797 (1984).	
	AT	Michelson, S., "Cytomegalovirus (CMV) and sequestration of chemokines," <i>Eur. Cytokine Netw.</i> , Vo. 10, No. 2, (June 1999), pp. 286-287.	
	AU	Schall, Thomas J., et al., "Chemokines, leukocyte trafficking, and inflammation", Curr. Opin. Immunol., Vol. 6, (1994), pp. 865-873.	
	AV	Schall, Thomas J., "Biology of the Rantes/SIS Cytokine Family", Cytokine, Vol. 3, No. 3 (May), (1991), pp. 165-183.	
Sad	AW	Wang, T. S. T., et al., "A simple Method of Preparation for [123]-(S)-(-)-IBZM, Appl. Radiat. Isot., No. 4, (1998), pp. 369-372.	

Examiner Signature	5958	Date Considered	7	123/	103	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

MAY 2 2 2003

PTO/SBOENTER 1600/290L

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Jiang, S. Anna

019934-000310US

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number						
Substitute for form 1449/PTO		Complete if Known				
	Application Number	09/944,163				
INFORMATION DISCLOSURE	Filing Date	August 30, 2001				
STATEMENT BY APPLICANT	First Named Inventor	Schall, Thomas J., et. al.				
		4047				

Examiner Name

Attorney Docket Number

U.S. PATENT DOCUMENTS

| Document Number | Publication Date | Name of Patentee or | Applicant of Cited Document | Pages, Columns, Lines, Where | Relevant Passages or Relevant | Pages, Columns, Lines, Where | Relevant Passages or Relevant | Figures Appear | T. Schall et al.

(use as many sheets as necessary)

2

		•		FOREIGN PA	TENT DOCUME	NTS		
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited	Pages, Columns, Lines, Where Relevant Passages or Relevant	76	
		Country Code ³	110,,,50,	Kind Code ⁵ (if known)		Document	Figures Appear	<u> </u>
	AB							$\sqcup \sqcup$
	AC							
	AD							
	AE							
	AF							
-	AG							

Examiner Signature	508	Date Considered	7/23/03	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.